Pegaptanib sodium for macular edema due to retinal-vein occlusion among patients intolerant to intravitreal triamcinolone acetonide

Authors

  • Ellen N. Yu, MD Asian Eye Institute Makati, Philippines Author
  • Pik Sha Chan, MD Asian Eye Institute Makati, Philippines Author
  • Amadeo A.S. Veloso, MD Asian Eye Institute Makati, Philippines Author
  • Harvey S. Uy, MD Asian Eye Institute Makati, Philippines; Department of Ophthalmology and Visual Sciences Sentro Oftalmologico Jose Rizal University of the Philippines–Philippine General Hospital Manila, Philippines Author

Keywords:

Retinal-vein occlusion, Macular edema, Intravitreal triamcinolone acetonide, anti-vascular endothelial growth factor (anti-VEGF)

Abstract

Objective: To report the efficacy and safety of intravitreal pegaptanib sodium (IVP) on macular edema (ME) due to branch retinal-vein occlusion (BRVO) among patients intolerant to intravitreal triamcinolone acetonide (IVTA).

Methods: Four eyes with ME due to BRVO were included in this interventional case series. The main outcome measures were best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and adverse effects.

Results: There was a significant decrease in mean CMT from 524.50 ± 141.12 to 293.75 ± 130.75 microns (p = 0.009) after IVP injection. BCVA improved in all 4 eyes after IVP. Mean IOP after IVP was 13.60 ± 3.21. No ocular or systemic complications were observed.

Conclusion: IVP appears to be safe and effective in decreasing retinal thickness and improving VA in eyes with ME due to BRVO. IVP is a potential treatment for eyes that are intolerant to IVTA.

Downloads

Published

2010-12-01

Issue

Vol. 35 No. 2

Section

Case Report

License

Copyright (c) 2010 Philippine Journal of Ophthalmology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.